Vergelijking

Eloralintide vs. Mazdutide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

2259884-03-0

Molecuulmassa

geen gegevens

4790 g/mol

Halfwaardetijd

geen gegevens

132 h

Sequentie

geen gegevens

synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkette

Werkingsmechanisme

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Mazdutide

Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Eloralintide	Mazdutide
CN	—	Op recept
Duitsland	Niet goedgekeurd	Alleen onderzoek
Verenigde Staten	Niet goedgekeurd	Alleen onderzoek

Volledige vermeldingen

Eloralintide

Volledige vermelding →

Mazdutide

Volledige vermelding →

Frequently asked questions

What is the difference between Eloralintide and Mazdutide?: Eloralintide is classified as "Metabool", while Mazdutide is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Mazdutide?: The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Mazdutide in Germany and the United States?: Duitsland: Eloralintide — Niet goedgekeurd, Mazdutide — Alleen onderzoek. Verenigde Staten: Eloralintide — Niet goedgekeurd, Mazdutide — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Mazdutide

—

Op recept

Duitsland

Niet goedgekeurd

Alleen onderzoek

Verenigde Staten

Niet goedgekeurd

Alleen onderzoek

Frequently asked questions

What is the difference between Eloralintide and Mazdutide?

Eloralintide is classified as "Metabool", while Mazdutide is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Mazdutide?

The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Mazdutide in Germany and the United States?

Duitsland: Eloralintide — Niet goedgekeurd, Mazdutide — Alleen onderzoek. Verenigde Staten: Eloralintide — Niet goedgekeurd, Mazdutide — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.